Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer

Journal of Gynecologic Oncology

Volumn 20, Issue 3, 2009, Pages 169-175

  Hwang, Jongyun ^a   Na, Sunghun ^a   Lee, Hyangah ^a   Lee, Dongheon ^a  

^a Kangwon National University   (South Korea)

Author keywords

CA 125; Insulin like growth factor II; Leptin; Osteopontin; Ovarian cancer biomarkers; Prolactin

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; LEPTIN; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREOPERATIVE PERIOD;

EID: 77953424542     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2009.20.3.169     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994; 1: 181-190
3. Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 2002; 107: 99-118.
4. Rapkiewicz AV, Espina V, Petricoin EF 3rd, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004; 40: 2604-2612
5. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 7677-7682
6. Menon U, Jacobs IJ. Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000; 12: 39-42. (Pubitemid 32260287)
7. Chambers AF, Vanderhyden BC. Ovarian cancer biomarkers in urine. Clin Cancer Res 2006; 12: 323-327
8. Goff BA, Muntz HG. Screenig and early diagnosis of ovarian cancer. Womens Health Prim Care 2005; 8: 262-268
9. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006; 12: 432-441 (Pubitemid 43166132)
10. Asai-Sato M, Nagashima Y, Miyagi E, Sato K, Ohta I, Vonderhaar BK, et al. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int J Cancer 2005; 115: 539-544 (Pubitemid 40656710)
11. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005; 90: 207-210
12. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91. (Pubitemid 19156368)
13. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621-632 (Pubitemid 33772040)
14. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999; 190: 1375-1382
15. Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep 2003; 10: 2015-2021
16. Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat 2004; 86: 191-196 (Pubitemid 39070961)
17. Mantovani G, Macdo A, Mura L, Massa E, Mudu MC, Mulas C, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78: 554-561 (Pubitemid 32039615)
18. Hegyi K, Fulop K, Kovacs K, Toth S, Falus A. Leptin-induced signal transduction pathways. Cell Biol Int 2004; 28: 159-169
19. Ruffion A, Al-Sakkaf KA, Brown BL, Eaton CL, Hamdy FC, Dobson PR. The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 2003; 43: 301-308 (Pubitemid 36314244)
20. Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 2004; 23: 1248-1255
21. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-4066 (Pubitemid 34044628)
22. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, Kalli KR, et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res 1998; 238: 439-449 (Pubitemid 28372832)
23. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004; 10: 1796-1806 (Pubitemid 38435571)
24. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004; 93: 361-365
25. But I, Gorisek B. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer. Gynecol Oncol 1996; 63: 166-172 (Pubitemid 26398594)
26. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86: 259-264
27. Rossi AC, Di Vagno G, Cormio G, Cazzolla A, Stefanelli S, D'Elia E, et al. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer. Arch Gynecol Obstet 2004; 269: 263-265 (Pubitemid 38661265)
28. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995; 21: 215-245
29. Stratton JF, Pharoah P, Tidy JA, Paterson ME. An analysis of ovarian tumor diameter and survival. Int J Gynecol Cancer 2000; 10: 449-451 (Pubitemid 32066626)
30. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-1072
31. Kim K, Visintin I, Alvero AB, Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med 2009; 29: 47-55.